Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:38:07.138Z.
Consensus retrieved: 2026-10-06T15:16:51.078Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:38:07.138Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1640542559587d997c0d8eaeaaf8c892bebef217736e9d4e66575bab6404537
Forward PE Ratio (N/A) = Dated Quote Price ($1.03) / Consensus Forward EPS ($-1.43)
FORWARD PE RATIO
N/A
Pliant Therapeutics, Inc.
Market Cap
$63.78M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | $63.78M | N/A |
| Alps Group Inc (ALPS)vs › | $64.18M | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | N/A |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | N/A |
| XBiotech Inc. (XBIT)vs › | $65.85M | N/A |
| Cingulate Inc. (CING)vs › | $65.86M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.03, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.43 | $-1.43 – $-1.42 | 2 | n/m |
| 2027-12-31 | $-1.36 | $-1.40 – $-1.30 | 2 | n/m |
| 2028-12-31 | $-1.07 | $-1.46 – $-0.68 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
